Skip to main content
XTL Biopharmaceuticals Ltd. (TLV:XTLB)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
3.000
0.00 (0.00%)
Dec 4, 2025, 4:41 PM IDT

XTL Biopharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Revenue
0.45----
Upgrade
Cost of Revenue
0.45----
Upgrade
Gross Profit
0----
Upgrade
Selling, General & Admin
2.080.730.8510.91
Upgrade
Research & Development
0.10.030.030.030.04
Upgrade
Operating Expenses
2.180.770.881.030.95
Upgrade
Operating Income
-2.17-0.77-0.88-1.03-0.95
Upgrade
Interest Expense
-0.03----
Upgrade
Interest & Investment Income
0.030.040.040.010.03
Upgrade
Currency Exchange Gain (Loss)
-0.03-0.03-0.020.010.01
Upgrade
Other Non Operating Income (Expenses)
-0.06-0-0.010.7-2.19
Upgrade
EBT Excluding Unusual Items
-2.25-0.76-0.87-0.31-3.09
Upgrade
Gain (Loss) on Sale of Investments
1.09-1.02-0.480.750.14
Upgrade
Pretax Income
-1.16-1.78-1.350.44-2.95
Upgrade
Income Tax Expense
-0.13----
Upgrade
Earnings From Continuing Operations
-1.03-1.78-1.350.44-2.95
Upgrade
Net Income
-1.03-1.78-1.350.44-2.95
Upgrade
Net Income to Common
-1.03-1.78-1.350.44-2.95
Upgrade
Shares Outstanding (Basic)
673545545532514
Upgrade
Shares Outstanding (Diluted)
704545545616514
Upgrade
Shares Change (YoY)
29.23%-0.00%-11.48%19.71%-
Upgrade
EPS (Basic)
-0.00-0.00-0.000.00-0.01
Upgrade
EPS (Diluted)
-0.00-0.00-0.000.00-0.01
Upgrade
Free Cash Flow
-1.67-0.71-0.9-1.05-0.85
Upgrade
Free Cash Flow Per Share
-0.00-0.00-0.00-0.00-0.00
Upgrade
Gross Margin
0.66%----
Upgrade
Operating Margin
-481.60%----
Upgrade
Profit Margin
-227.72%----
Upgrade
Free Cash Flow Margin
-370.73%----
Upgrade
EBITDA
-1.97-0.76-0.88-1.03-0.95
Upgrade
D&A For EBITDA
0.20000
Upgrade
EBIT
-2.17-0.77-0.88-1.03-0.95
Upgrade
Advertising Expenses
0.16----
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.